Dow Jones-Bayer has received approval for a new indication from the US drug supervisory authority FDA for the Medicine Finerenon (brand: Kerendia). The FDA approved Finerenon for patients with heart failure and a so-called left ventricular outfield (LVEF) of at least 40 percent, said the Leverkusen pharmaceutical and chemical group. The approval has now taken place after Finerenon had delivered positive results in a phase III storm. The FDA had previously approved the status of an accelerated test procedure for finerenon.
According to Bayer, around 3.7 million people in the United States live with heart failure with an LVEF of at least 40 percent. This leads to more than 500,000 hospital stays per year. So far, the treatment options for this have been limited.
Finerenon or the Kerendia brand in the United States has been approved for the treatment of adult patients with chronic kidney disease in connection with type 2 diabetes since 2021.
Contact to the author: [email protected]
DJG/UXD/APO
(End) Dow Jones Newswires
July 14, 2025 03:38 ET (07:38 GMT)
Selected leverage products on Bayer
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Bayer
The lever must be between 2 and 20
Advertising